SLFN11 and neoplasm: Given the limited availability of tumor biopsies in advanced SCLC, SLFN11 expression in circulating tumor cells (CTCs) is a noninvasive biomarker for monitoring treatment response and resistance, facilitating personalized therapeutic strategies [134].